CHMMF (Chimeric Therapeutics) Total Stockholders Equity : $3.76 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Total Stockholders Equity?

Chimeric Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $3.76 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Chimeric Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 was $0.00. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Chimeric Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.00.

Chimeric Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Chimeric Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Total Stockholders Equity Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Jun24

Total Stockholders Equity

19.21

18.57

4.08

1.64

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial			10.77	4.08	9.28	1.64	3.76

Chimeric Therapeutics (OTCPK:CHMMF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Chimeric Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(3.762	-	0)	/	1653.907
	=	0.00

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Chimeric Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	3.762
	=	0.00

Chimeric Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (OTCPK:CHMMF) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

CHM:Australia

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics Headlines

From GuruFocus

Chimeric Therapeutics Ltd FNN Investor Event Transcript

By GuruFocus Research • 02-13-2024

Chimeric Therapeutics Ltd Investor Webinar Transcript

By GuruFocus Research • 02-13-2024

Chimeric Therapeutics Ltd at NWR Communications Virtual Conference Transcript

By GuruFocus Research • 02-13-2024